Combat Medical, a UK-based medical device company specializing in hyperthermic intravesical chemotherapy (HIVEC®), has secured £2.6 million in its first close of Series A funding. Led by the T&J Meyer Family Foundation and joined by Varia Ventures, NW Angel Fund, and other investors, the capital will support the ongoing pivotal FDA registration trial HIVEC-HEAT. This Phase 3 study evaluates HIVEC® for patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), aiming to deliver a bladder-sparing, effective, and affordable alternative amid growing demand for non-surgical options in this challenging patient population.
Combat Medical Secures Funding Boost for Pivotal Bladder Cancer Trial
The recent funding round marks a significant milestone for Combat Medical as it pushes forward with efforts to address one of the most pressing unmet needs in urologic oncology: effective treatments for BCG-unresponsive NMIBC. This condition affects a substantial portion of patients with high-risk non-muscle-invasive bladder cancer who fail standard Bacillus Calmette-Guérin (BCG) therapy, leaving them at high risk of progression to muscle-invasive disease and often facing radical cystectomy as the primary option.
Combat Medical’s HIVEC® technology enhances intravesical chemotherapy by combining it with controlled hyperthermia. The system recirculates heated chemotherapy agents directly within the bladder, optimizing drug penetration and efficacy while minimizing systemic exposure. This approach has shown promise in earlier studies for improving response rates in NMIBC, particularly in settings where BCG has proven insufficient.
The HIVEC-HEAT trial serves as the company’s flagship clinical program, designed as a pivotal registration study to support FDA approval. By targeting BCG-unresponsive patients, the trial focuses on demonstrating durable responses, bladder preservation, and favorable safety profiles. Success could position HIVEC® as a practical addition to the evolving landscape of intravesical therapies, offering urologists a device-based solution that integrates seamlessly into outpatient settings.
Bladder cancer remains one of the most common malignancies in the United States, with NMIBC accounting for approximately 75% of new diagnoses. High-risk NMIBC patients who become unresponsive to BCG face limited approved options, including intravesical gene therapies, oncolytic immunotherapies, and systemic checkpoint inhibitors. Recent years have seen approvals for treatments like nadofaragene firadenovec, pembrolizumab, and combinations such as BCG with IL-15 agonists, yet challenges persist around durability, accessibility, toxicity, and cost.
Hyperthermic approaches like HIVEC® build on established principles of heat-enhanced chemotherapy, where mild hyperthermia (typically 42-43°C) increases cellular sensitivity to drugs, disrupts tumor vasculature, and boosts immune responses. In bladder applications, this method aims to overcome limitations of standard room-temperature instillations, such as poor drug distribution and limited penetration into deeper tissue layers.
The funding will primarily advance the HIVEC-HEAT trial, including patient enrollment, data collection, and regulatory milestones. Combat Medical’s strategy emphasizes rigorous evidence generation to support broad adoption, particularly in markets where BCG shortages and high costs of newer therapies create barriers.
Key advantages of the HIVEC® platform include:
Bladder-sparing potential — Reducing the need for cystectomy in suitable candidates.
Outpatient compatibility — Enabling administration in urology clinics without specialized surgical infrastructure.
Targeted delivery — Minimizing systemic side effects compared to intravenous options.
Cost considerations — Positioning as a potentially more affordable alternative in resource-constrained environments.
As the trial progresses, interim and final results will provide critical insights into complete response rates, recurrence-free survival, and quality-of-life impacts. The company’s global experience, with devices used in over 40 countries for bladder and peritoneal cancers, supports its capability to scale if regulatory clearance is achieved.
This investment reflects growing investor confidence in innovative device-based solutions for oncology, especially in urology where intravesical delivery offers direct tumor access. For patients with BCG-unresponsive disease, advancements like HIVEC® represent hope for more effective, less invasive management strategies that prioritize bladder preservation and long-term outcomes.
Disclaimer: This article is for informational purposes only and does not constitute medical advice, investment recommendation, or endorsement of any product or company. Bladder cancer treatment decisions should be made in consultation with qualified healthcare professionals based on individual circumstances.
Leave a Reply